neurodegenerative diseases

role-of-plasma-protein-therapeutics

Oct 23, 2024

Plasma Proteins Therapeutics: Transforming Treatment in Hematology and Beyond

potential-of-exosomes

Oct 21, 2024

Exosomes: Tiny Messengers with Big Potential in Medical Science

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna

Dec 19, 2023

Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

Creutzfeldt-Jakob disease (CJD)

Dec 26, 2018

‘Transmissible’ Alzheimer’s theory gains traction

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper